Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australian Initiative Aims To Educate On Biosimilars

Second ‘Biosimilar Awareness Week’ Launching In Late May

Executive Summary

Australia’s GBMA is rolling out its second annual “Biosimilar Week” later this month as part of a three-year education program being pursued by the association and industry stakeholders.

You may also be interested in...



Australia Rolls Out Second ‘Biosimilars Week’

A series of educational events and messages are being rolled out by Australia’s GBMA industry association as part of “Biosimilar Awareness Week.”

GBMA Plans Workshop As Part Of Biosimilars Education

Australia’s GBMA is continuing to push forward with education efforts on biosimilars, scheduling for early October a multi-disciplinary workshop with the support of local health minister Greg Hunt.

Australia Rolls Out Resources In ‘Biosimilar Week’

Australia’s GBMA has provided healthcare professionals with a host of educational resources on biosimilars as part of its ‘Biosimilar Week’ campaign.

Related Content

Topics

UsernamePublicRestriction

Register

LL065251

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel